SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Bion Environmental Technologies settled material litigation with Hamstra Builders, Inc. related to construction of the Fair Oaks facility, with mechanics liens and litigation that commenced in April 2025. The settlement involves issuance of a $1.77M convertible note and extension of existing debt maturities, which the CEO characterized as among the company's largest challenges.
View raw filing on EDGAR →Valerie Greer, Executive Vice President and Chief Commercial Officer, has provided notice of her intent to retire effective February 19, 2027, after nearly four decades in financial services and six years with Bread Financial. The retirement agreement includes severance and benefits, and her departure is material to investors assessing leadership continuity.
View raw filing on EDGAR →Jon Lin, Chief Business Officer, is separating from employment effective July 18, 2026. The disclosure centers on his departure and associated severance entitlements under the Executive Severance Plan. While a transition plan and future CPO appointment are mentioned, the principal disclosed action is the departure of a named executive officer.
View raw filing on EDGAR →Alto Neuroscience entered into an underwriting agreement to issue 3,776,436 shares of common stock in a registered direct offering at $26.48 per share, generating approximately $93.9 million in net proceeds. This is a registered equity issuance that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing strategy.
View raw filing on EDGAR →NextCure entered into a definitive merger agreement with Avere Therapeutics on July 14, 2026, whereby NextCure will acquire Avere in an all-stock transaction. The combined company will operate as Avere Therapeutics, with NextCure stockholders owning approximately 1.21% post-closing, accompanied by a concurrent $320 million private placement financing and expected to close in H2 2026.
View raw filing on EDGAR →NextCure's Board approved a restructuring and workforce reduction plan affecting a substantial majority of the company's workforce during Q3 2026, with expected one-time charges of approximately $1.9 million primarily for employee severance and termination costs.
View raw filing on EDGAR →The Company announced formation of a special committee of independent directors to evaluate strategic alternatives "which may include a possible transaction involving the Company." The retention of financial advisor Solomon Partners and legal advisor Willkie Farr & Gallagher LLP to assist with the strategic review process signals active consideration of M&A activity. While no transaction has been entered into yet, the initiation of a formal strategic review process evaluating potential acquisitions, mergers, or other transactions is a material disclosure that would affect a reasonable investor's assessment of the registrant's future direction.
View raw filing on EDGAR →The filing discloses a material milestone in a merger transaction: on July 13, 2026, the U.S. Department of Justice granted early termination of the Hart-Scott-Rodino Act waiting period for RE/MAX Holdings' proposed merger with The Real Brokerage Inc. This represents a significant regulatory clearance event in the completion of the contemplated transaction, removing a key closing condition. The merger agreement was entered into on April 26, 2026, and this disclosure documents progress toward consummation of the transaction.
View raw filing on EDGAR →The 6-K discloses a material acquisition transaction: Real Brokerage Inc. entered into a Merger Agreement with RE/MAX Holdings on April 26, 2026, and on July 13, 2026, the U.S. Department of Justice granted early termination of the HSR Act waiting period, clearing a major regulatory hurdle toward completion. The filing provides detailed disclosure of the transaction structure, regulatory approvals obtained, and remaining closing conditions, consistent with Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition) disclosure obligations.
View raw filing on EDGAR →This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.
View raw filing on EDGAR →MDA Space closed a bought deal offering of 23 million common shares at US$35.60 per share, raising approximately US$819 million in gross proceeds. The company explicitly states it intends to use net proceeds to fund a portion of the purchase price for its acquisition of approximately 70% interest in Collecte Localisation Satellites (CLS). This is a material dilutive equity issuance directly tied to financing a significant M&A transaction, with an over-allotment option for up to 15% additional shares.
View raw filing on EDGAR →Citigroup disclosed its second quarter 2026 financial results on July 14, 2026, reporting net income of $5.8 billion (up 45% year-over-year) and revenues of $24.8 billion (up 14% year-over-year). The press release, filed as Exhibit 99.1, contains detailed financial statements, segment performance, and CEO commentary on quarterly results. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →Evan Cutler's employment with Highline ended on June 30, 2026, and he ceased serving as the Partnership's principal financial and accounting officer. This is a clear departure of a named executive officer (CFO/principal financial officer) from the registrant, disclosed under Item 5.02. The departure is material given the officer's role and the company's receivership status.
View raw filing on EDGAR →Evan Cutler's departure as Chief Financial Officer of Highline and cessation of service as the Partnership's principal financial and accounting officer on June 30, 2026 constitutes an executive departure. The filing explicitly states his employment ended "as part of and in accordance with the wind-down process," confirming the departure of a named officer responsible for principal financial and accounting functions. While the company is in receivership, the departure of the CFO/principal financial officer is material to investors assessing the registrant's financial oversight and operational status.
View raw filing on EDGAR →This exhibit is a business update and operational disclosure for Q2 2026 that includes preliminary financial metrics (order intake €30.7M, revenues €27.7M, order backlog €54.8M) and updated full-year 2026 guidance (revenues >€100M, EBITDA margin >12%, order intake guidance increased from ~€114M to €125-€150M). While labeled an "operational update" rather than a formal earnings release, it discloses preliminary Q2 and H1 financial results with forward guidance, which is material to investors assessing the company's performance trajectory. The company notes final results will be published by August 25, 2026.
View raw filing on EDGAR →This exhibit is a monthly operational and financial update disclosing June 2026 bitcoin mining production (64 BTC), cryptocurrency treasury holdings (1,915 BTC and 3,952 ETH), hashrate metrics, and facility efficiency data. While it includes routine operational metrics, the disclosure of record cryptocurrency holdings, joint venture recovery from wildfire disruptions, and strategic updates on hash-to-heat technology deployment and Nasdaq Capital Market transfer constitute material operational and strategic developments affecting investor assessment of the company's mining operations and financial position. The exhibit does not fit discrete event categories (not earnings, not M&A, not exec changes) but represents a material operational update on mining performance and strategic initiatives.
View raw filing on EDGAR →D-MARKET has scheduled an Extraordinary General Assembly Meeting for August 14, 2026, to authorize a material share capital increase of TRY 9.3 billion (increasing authorized shares from 361.8M to 433.3M) and to amend the Articles of Association, with disapplication of pre-emptive rights for The Bank of New York Mellon as depositary.
View raw filing on EDGAR →The filing discloses compensatory arrangements for two named executives: Christopher V. Vitale (CEO) received a $178,000 cash bonus and 8,700 restricted shares vesting over three years, while Adrienne M. Uleau (CFO) received a $64,000 cash bonus and 2,250 restricted shares on the same schedule. Additionally, the Company approved salary increases for both executives effective July 27, 2026 ($395,000 for Vitale and $205,000 for Uleau). These are classic equity grants and compensation plan amendments under Item 5.02(e).
View raw filing on EDGAR →Kelly E. Garcia was appointed as Chief Technology Officer of Ulta Beauty, effective August 31, 2026, bringing more than 25 years of leadership experience in e-commerce, customer loyalty, digital innovation, and cybersecurity to support the company's technology strategy.
View raw filing on EDGAR →The 6-K discloses the appointment of two new directors effective July 10, 2026: Ms. Mei Ting Yeung (appointed as director, Chair of the Audit Committee, and committee member) and Mr. Wei Li (appointed as director and committee member). While the filing also mentions two concurrent resignations, the principal disclosed action is the appointment of these new board members with detailed biographical information and committee assignments. The appointments are material to investors as they affect board composition and audit committee leadership.
View raw filing on EDGAR →Item 2.02 discloses Elite Express Holding Inc.'s quarterly financial results for the period ended May 31, 2026, with a press release furnished as Exhibit 99.1. The disclosure includes detailed revenue ($726,829), cost of revenue ($645,792), gross profit ($81,037), operating expenses ($2,856,072), and net loss ($2,532,942) for the three-month period, along with comparative prior-year data and consolidated financial statements. This is a standard earnings release disclosure material to investors assessing the registrant's operational and financial performance.
View raw filing on EDGAR →AutoZone completed the sale of $850 million in aggregate principal amount of 4.950% Senior Notes due 2031 on July 14, 2026, creating a new direct financial obligation with specified interest rate, maturity date, covenants, and redemption provisions.
View raw filing on EDGAR →Archimedes Tech SPAC Partners II Co. disclosed a PIPE (private investment in public equity) financing whereby the company will sell 2,300,000 shares of common stock at $10.00 per share for approximately $23 million in gross proceeds, contingent upon closing of the proposed business combination with Forge Nano. This brings total PIPE commitments to $123 million ahead of the expected NASDAQ listing. The subscription agreements contain customary terms including registration rights and anti-dilution provisions.
View raw filing on EDGAR →The filing discloses a declaration by the Trustees of Mesabi Trust of a distribution of $0.05 per Unit payable on August 20, 2026 to unitholders of record as of July 30, 2026. This is a routine periodic distribution to beneficial interest holders. Although the distribution amount declined significantly from $0.12 per unit in the prior year (reflecting lower royalty payments from Cleveland-Cliffs), the core event is the declaration and payment of a distribution to security holders, which is material to investors in a trust that derives its value primarily from distributions.
View raw filing on EDGAR →This press release announces completion of the first production blast at the Mesabi Metallics iron ore project, a key operational milestone for TMCR's royalty asset. The disclosure is material because it marks the transition from construction to production phase and signals the imminent commencement of royalty revenue generation (anticipated at ~$11 million annually), which is central to TMCR's business model as a royalty financing platform. While not fitting a discrete event category like M&A or earnings, this operational milestone directly affects investor assessment of the Company's path to profitability and cash flow generation.
View raw filing on EDGAR →Capricor entered into a material lease agreement for approximately 171,000 square feet at 9625 Towne Centre Drive, San Diego, to serve as its new headquarters with expanded manufacturing and R&D facilities. The lease involves approximately $958,000 monthly base rent over a 138-month term with an 18-month rent abatement, representing a significant operational and financial commitment.
View raw filing on EDGAR →The Company announces exercise of a repurchase option on Tier 1 Subordinated perpetual Financial Bills totaling BRL 1.4 billion, issued in 2019. This is a material capital management action affecting the Company's Tier 1 capital ratio by approximately 10 basis points. While technically a redemption/repurchase rather than a new issuance, it represents a material modification of the Company's direct financial obligations and capital structure, most closely aligned with debt_issuance in the taxonomy as it involves a significant debt instrument transaction.
View raw filing on EDGAR →AngioDynamics issued a press release on July 14, 2026 announcing financial results for the fiscal fourth quarter and full year ended May 31, 2026, including net sales of $320.2M (9.4% growth), gross margin of 54.6%, adjusted EBITDA of $13.2M, and forward-looking guidance for fiscal 2027 net sales of $336.0M–$341.0M.
View raw filing on EDGAR →Stephen Mackintosh resigned as Chief Investment Officer effective July 8, 2026. The resignation was not due to any disagreement with the Company on financial reporting, operations, policies, or practices.
View raw filing on EDGAR →The 6-K announces a debt exchange offer whereby Murano Global Investments PLC is offering to exchange outstanding 11.000% Senior Secured Notes due 2031 for new Fixed Rate Senior Secured Notes due 2032, coupled with a concurrent consent solicitation. This constitutes creation of a new direct financial obligation (the New Notes) and modification of existing debt terms, which falls under debt_issuance. The exchange and consent solicitation are material refinancing activities that would affect investor assessment of the registrant's capital structure and obligations.
View raw filing on EDGAR →Vistra disclosed results from the PJM Capacity Auction for planning year 2028/2029, clearing approximately 10,924 MW at a weighted average price of $325.00/MW-day across multiple zones. This represents a material operational and financial outcome for a power generation company, as capacity auction results directly affect future revenue streams and market positioning. While not fitting a specific named event type, this is clearly an operational/strategic business milestone that would affect a reasonable investor's assessment of the company's market performance and forward revenue visibility.
View raw filing on EDGAR →This is a press release announcing Grupo Aeroportuario del Pacífico's consolidated financial results for the second quarter ended June 30, 2026. The document presents detailed revenue, operating cost, and net income figures comparing 2Q26 to 2Q25, along with EBITDA, margins, and per-share metrics. While the results also reference a material business combination (CBX merger effective May 1, 2026), the primary disclosure is the quarterly earnings announcement, which is a discrete earnings release event material to investors.
View raw filing on EDGAR →This is an announcement of an upcoming earnings release for Q2 2026, scheduled for July 30, 2026. While the actual financial results are not disclosed in this exhibit, the press release explicitly states "Codere Online to Release Financial Results for the Second Quarter 2026 on July 30th" and confirms that "The Company's earnings press release and related materials will be available on Codere Online's website." This is a notice of a forthcoming earnings announcement, which is material to investors as quarterly results disclosure affects the total mix of information available about the registrant's financial performance.
View raw filing on EDGAR →This is a press release announcing second-quarter 2026 production results for Trekor's Gibraltar and Florence Copper operations. The disclosure reports specific production volumes (30.3 million pounds of copper from Gibraltar, 5.2 million pounds from Florence Copper), sales figures, and updated annual guidance (110–115 million pounds for Gibraltar; 30–35 million pounds for Florence Copper). This is a discrete operational and financial results announcement typical of an earnings release, material to investors assessing the company's operational performance and ability to meet guidance.
View raw filing on EDGAR →America's Car-Mart issued a press release on July 14, 2026 announcing operating results for the fourth quarter and fiscal year ended April 30, 2026, disclosing total revenue of $1,281.5 million (down 7.9%), sales volumes of 48,891 units (down 14.3%), and a loss per share of $16.79. This is a standard earnings release disclosure under Item 2.02, attached as Exhibit 99.1 and furnished in accordance with General Instruction B.2.
View raw filing on EDGAR →Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America on July 10, 2026, establishing a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031, and an option to request up to an additional $50.0 million for a maximum of $100.0 million.
View raw filing on EDGAR →Tower Semiconductor announces a strategic dual-track capacity expansion in Japan with Government of Japan (METI) support, involving repurposing the Arai facility for 300mm Silicon Photonics and constructing an adjacent new 300mm manufacturing facility. The company updates its 2028 business model to target $3.6 billion revenue and $1.2 billion net profit, with approximately $3 billion in Tower investment net of $1 billion in government grants. This is a material operational and strategic business event involving significant capital investment, facility expansion, and revised financial guidance, but does not fit the specific categories of M&A activity, debt issuance, or other named event types.
View raw filing on EDGAR →The 6-K discloses a material cybersecurity incident involving unauthorized exfiltration of backup data, including payment transaction records and business information, following an initial announcement on July 8, 2026. Although the Company confirms systems are now cleared, production environment unimpacted, and customer funds untouched, the incident involved data exfiltration, criminal extortion demands, and ongoing investigation costs—hallmarks of a material cybersecurity breach requiring disclosure under Item 1.05 (required since 2023).
View raw filing on EDGAR →TAT Technologies announced an expansion of its strategic relationship with Honeywell Aerospace, becoming the sole global authorized distributor of spare parts for the GTCP 331-200/250 APU platform, extending MRO licenses until 2036, and acquiring three APUs for its trading and leasing business. This is a material operational and commercial milestone—a significant partnership expansion and distribution agreement—that does not fit the specific event categories (M&A, debt, equity, litigation, etc.) but clearly affects the registrant's business strategy and revenue prospects in its core aerospace aftermarket segment.
View raw filing on EDGAR →SuperCom announced a registered direct offering of 732,683 ordinary shares at $10.25 per share, raising approximately $7.5 million in gross proceeds. This is a registered equity issuance under the company's Form F-3 shelf registration statement, which dilutes existing shareholders. The offering is material to investors as it represents a significant capital raise and shareholder dilution event.
View raw filing on EDGAR →QTREX announced receipt of a commercial purchase order from a leading international government-owned company for customized Shielded RF Monolithic components. The disclosure emphasizes this as a strategic expansion of the company's commercial model into direct supply of proprietary, application-specific components, with production underway and delivery expected within days. While this is a material operational and commercial milestone demonstrating market validation and revenue generation, it does not fit the specific event-type categories (not M&A, not a financial obligation, not a restructuring). This is a material contract/commercial milestone that would affect a reasonable investor's assessment of the company's business trajectory and revenue prospects.
View raw filing on EDGAR →The 6-K discloses the results of an extraordinary general meeting of shareholders held on July 14, 2026, with detailed voting tallies for five proposals. All proposals passed, including a significant increase in authorized share capital (from US$50,000 to US$2,500,000), approval of share consolidations at ratios between 1-for-10 and 1-for-250, and amendments to the memorandum and articles of association. These capital structure changes are material to investors' assessment of the company's equity and voting rights.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the Company's annual stockholder meeting held on July 8, 2026, including election of two Class I Directors (Bradley V. Stoots and Steven G. Hooser), ratification of HoganTaylor LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents voting tallies for each matter, which is the core content of shareholder vote results disclosures.
View raw filing on EDGAR →Unity Bancorp issued a press release on July 14, 2026 announcing quarterly and six-month financial results for the period ended June 30, 2026. The disclosure includes net income of $14.5 million ($1.42 per diluted share) for Q2 2026 and $28.8 million ($2.82 per diluted share) for the six-month period, along with detailed financial highlights, balance sheet data, and performance metrics. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →SemiLEDs issued a press release on July 14, 2026 announcing preliminary financial results for the third quarter ended May 31, 2026, disclosing revenue of $9.1 million, GAAP net income of $1.5 million ($0.18 per diluted share), and key metrics including gross margin (27%) and operating margin (16%). The filing includes unaudited condensed consolidated balance sheets and statements of operations, which are typical exhibits for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →Mercer Torgau, an indirectly wholly-owned subsidiary of Mercer International Inc., announced strategic actions involving a workforce reduction of approximately 350 positions overall, with an initial reduction of approximately 100 contractor positions in July 2026, to be completed in stages by Q2 2027. The disclosure explicitly addresses operational restructuring and workforce reduction, which are material to investors assessing the registrant's operational efficiency and cost structure.
View raw filing on EDGAR →CleanSpark entered into a 20-year triple-net lease agreement with a high-investment-grade global technology company for 175 MW of data center infrastructure at its Sandersville, Georgia campus, generating $6.6 billion in contracted revenue over the initial term with up to $11.6 billion including extension options, plus an exclusivity arrangement covering its 885 MW Texas portfolio. This represents a transformational operational and strategic milestone for the company's data center business model.
View raw filing on EDGAR →Spero entered into an exclusive license agreement with Innovent Biologics on July 8, 2026, acquiring worldwide rights (excluding Greater China) to develop, manufacture, and commercialize SP001, a Phase 2-ready anti-CD40L monoclonal antibody. The transaction includes an upfront payment of $35 million, up to $1.05 billion in milestone payments, and tiered royalties, establishing the foundation of Spero's new immunology pipeline.
View raw filing on EDGAR →Spero entered into a $105 million non-recourse royalty financing transaction with Healthcare Royalty (a KKR affiliate), receiving $105 million in exchange for rights to future milestone and royalty payments from Utebzi sales, with Healthcare Royalty receiving quarterly principal and interest payments derived from GSK payments.
View raw filing on EDGAR →Apollomics announced on July 8, 2026, that it "regained compliance" with Nasdaq's Market Value of Listed Securities (MVLS) requirement after receiving a non-compliance notice on June 18, 2026, for failing to maintain the $35 million minimum. The press release explicitly states "the matter is now closed," confirming resolution of a delisting risk that threatened the company's continued listing on the Nasdaq Capital Market.
View raw filing on EDGAR →